Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on January 29, 2008
JNCI Journal of the National Cancer Institute 2008 100(3):224-225; doi:10.1093/jnci/djm302
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/3/224    most recent
djm302v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ichikawa, W.
Right arrow Articles by Sasaki, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ichikawa, W.
Right arrow Articles by Sasaki, Y.
Related Collections
Right arrowRelated Article in JNCI
Right arrowResponse to this Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

CORRESPONDENCE

Re: UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters

Wataru Ichikawa, Kazuhiro Araki, Ken-Ichi Fujita, Wataru Yamamoto, Hisashi Endo, Fumio Nagashima, Ryuhei Tanaka, Toshimichi Miya, Keiji Kodama, Yu Sunakawa, Masaru Narabayashi, Yuichi Ando, Yuko Akiyama, Kaori Kawara, Yasutsuna Sasaki

Affiliations of authors: Department of Medical Oncology, Comprehensive Cancer Center (WI, KA, KF, WY, HE, FN, RT, TM, K. Kodama, Y. Sunakawa, MN, Y. Ando, Y. Akiyama, K. Kawara, Y. Sasaki) and Project Research Laboratory, Research Center for Genomic Medicine (KF, Y. Sasaki), Saitama Medical University, Saitama, Japan

Correspondence to: Wataru Ichikawa, MD, Department of Medical Oncology, Comprehensive Cancer Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan (e-mail: wataru@saitama-med.ac.jp).

The first 10% of the full text of this article appears below.

We read with interest the paper from Hoskins et al. (1) on the meta-analysis of the studies that assessed the association of irinotecan dose with the risk of irinotecan-related toxic effects for patients with the UGT1A1*28/*28 genotype. They indicated that the risk of hematologic toxicity was strongly associated with UGT1A1*28 genotype at higher irinotecan doses (>150 mg/m2), not at lower doses (≤150 mg/m2).

. . . [Full Text of this Article]

Funding


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters
Janelle M. Hoskins, Richard M. Goldberg, Pingping Qu, Joseph G. Ibrahim, and Howard L. McLeod
J Natl Cancer Inst 2007 99: 1290-1295. [Abstract] [Full Text] [PDF]

Response to this Correspondence

Response
Janelle M. Hoskins and Howard L. Mcleod
J Natl Cancer Inst 2008 100: 225. [Extract] [Full Text] [PDF]